Big biotech, Biotech, Partnering

Big biotech, Alynylam Pharma collaboration with Alpha-1 project

Posted on 20 June 2014

Tags: ,

Alnylam Pharmaceuticals and The Alpha-1 Project have entered into a collaboration agreement for the continued advancement of ALN-AAT.

ALN-AAT is a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

TAP’s mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency.

TAP is partially funding research activities for ALN-AAT.

Detailed financial terms of the research agreement were not disclosed.

Alnylam remains on track to file an investigational new drug application for this program in mid-2015.

For further deal information visit Current Agreements (subscription required)


Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply